chimerix
reports
third
quarter
financial
results
provides
operational
update
completed
rolling
nda
submissions
bcv
tablet
suspension
formulations
medical
countermeasure
smallpox
first
patient
visit
dstat
phase
aml
study
expected
early
company
well
capitalized
several
expected
upcoming
milestones
conference
call
et
today
durham
globe
newswire
chimerix
nasdaq
cmrx
biopharmaceutical
company
focused
accelerating
development
medicines
treat
cancer
serious
diseases
today
reported
financial
results
third
quarter
ended
september
provided
operational
update
throughout
third
quarter
continued
make
significant
progress
across
number
key
initiatives
said
mike
sherman
chief
executive
officer
chimerix
particular
note
completion
rolling
submissions
food
drug
administration
fda
approval
brincidofovir
bcv
medical
countermeasure
smallpox
milestone
brings
us
one
step
closer
company
first
regulatory
approval
securing
potential
procurement
contract
barda
supply
strategic
national
stockpile
sns
expect
take
place
around
time
potential
fda
approval
addition
expect
notified
prescription
drug
user
fee
act
pdufa
date
relating
submissions
end
addition
expect
initiate
phase
study
dstat
treatment
acute
myeloid
leukemia
aml
early
particularly
encouraged
recent
patients
covering
separate
studies
published
journal
american
medical
association
oncology
short
et
al
link
suggested
minimal
residual
disease
mrd
status
outcomes
patients
aml
specifically
large
cohort
showed
aml
patients
experience
superior
survival
overall
survival
rates
compared
patients
average
hazard
ratios
overall
survival
survival
respectively
study
suggests
evaluation
mrd
status
aml
patients
may
allow
earlier
assessment
therapeutic
effects
could
lead
acceleration
development
novel
aml
therapeutics
underscores
importance
mrd
assessment
undertake
following
first
evaluable
patients
phase
study
order
better
interpret
survival
overall
survival
advantages
observed
dstat
smaller
phase
due
complex
rapidly
changing
landscape
current
pandemic
predict
complete
enrollment
phase
trial
dstat
acute
lung
injury
ali
anticipate
sharing
initial
topline
data
first
quarter
concluded
sherman
recent
highlights
completed
rolling
nda
submissions
bcv
tablets
bcv
suspension
medical
countermeasure
smallpox
published
manuscript
advances
therapy
titled
design
rationale
randomized
phase
study
evaluating
dociparstat
acute
lung
injury
associated
severe
presented
data
support
modeling
simulation
approach
used
determine
bcv
dosing
treatment
smallpox
humans
world
health
organization
advisory
committee
variola
virus
research
expected
upcoming
milestones
fda
notification
fourth
quarter
regarding
acceptance
bcv
nda
submissions
assignment
pdufa
date
initiation
phase
trial
dstat
first
line
aml
early
potential
procurement
agreement
bcv
around
time
fda
decision
smallpox
nda
fda
decision
bcv
smallpox
nda
completion
phase
trial
dstat
related
ali
completion
bcv
drug
product
manufacturing
support
potential
shipments
sns
million
third
quarter
financial
results
chimerix
reported
net
loss
million
per
basic
diluted
share
third
quarter
period
chimerix
recorded
net
loss
million
per
basic
diluted
share
revenues
third
quarter
decreased
million
compared
million
period
research
development
expenses
increased
million
third
quarter
compared
million
period
increase
driven
clinical
trial
expenses
associated
development
dstat
general
administrative
expenses
decreased
million
third
quarter
compared
million
period
loss
operations
million
third
quarter
compared
loss
operations
million
period
included
million
associated
licensing
dstat
period
chimerix
balance
sheet
september
included
million
capital
available
fund
operations
debt
approximately
million
outstanding
shares
common
stock
conference
call
webcast
chimerix
host
conference
call
live
audio
webcast
discuss
third
quarter
financial
results
provide
business
update
today
et
access
live
conference
call
please
dial
domestic
international
least
five
minutes
prior
start
time
refer
conference
id
live
audio
webcast
call
also
available
investors
section
chimerix
website
archived
webcast
available
chimerix
website
approximately
two
hours
event
chimerix
chimerix
biopharmaceutical
company
dedicated
accelerating
advancement
innovative
medicines
make
meaningful
impact
lives
patients
living
cancer
serious
diseases
two
development
programs
dociparstat
sodium
dstat
brincidofovir
bcv
dstat
potential
glycosaminoglycan
compound
derived
porcine
heparin
compared
commercially
available
forms
heparin
may
dosed
higher
levels
without
associated
complications
dstat
studied
phase
trial
assess
safety
efficacy
adults
acute
lung
injury
underlying
phase
trial
protocol
study
dstat
acute
myeloid
leukemia
developed
alignment
us
food
drug
administration
fda
first
patient
visit
expected
early
bcv
antiviral
drug
candidate
developed
potential
medical
countermeasure
smallpox
currently
review
regulatory
approval
united
states
information
please
visit
chimerix
website
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
subject
risks
uncertainties
could
cause
actual
results
differ
materially
projected
statements
include
relating
among
things
chimerix
ability
obtain
regulatory
approval
bcv
timing
receipt
potential
procurement
contract
bcv
smallpox
initiation
progress
results
phase
clinical
trial
dstat
aml
phase
clinical
trial
dstat
ali
associated
among
factors
risks
could
cause
actual
results
differ
materially
indicated
statements
risks
dstat
may
obtain
regulatory
approval
fda
approval
may
delayed
conditioned
risks
development
activities
related
dstat
may
completed
time
risks
dstat
may
achieve
endpoints
clinical
trials
risks
chimerix
obtain
procurement
contract
bcv
smallpox
timely
manner
chimerix
reliance
sole
source
manufacturer
drug
supply
risks
ongoing
future
trials
may
successful
replicate
previous
trial
results
may
predictive
results
results
subsequent
trials
risks
uncertainties
relating
competitive
products
technological
changes
may
limit
demand
drugs
risks
drugs
may
precluded
commercialization
proprietary
rights
third
parties
additional
risks
set
forth
company
filings
securities
exchange
commission
statements
represent
company
judgment
date
release
company
disclaims
however
intent
obligation
update
statements
contact
investor
relations
michelle
laspaluto
ir
connor
stern
investor
relations
media
david
schull
russo
partners
chimerix
consolidated
balance
sheets
thousands
except
share
per
share
data
unaudited
september
december
assets
current
assets
cash
cash
equivalents
investments
accounts
receivable
prepaid
expenses
current
assets
total
current
assets
property
equipment
net
accumulated
depreciation
operating
lease
assets
assets
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
accrued
liabilities
total
current
liabilities
obligations
total
liabilities
stockholders
equity
preferred
stock
par
value
shares
authorized
september
december
shares
issued
outstanding
september
december
common
stock
par
value
shares
authorized
september
december
shares
issued
outstanding
september
december
respectively
additional
capital
accumulated
comprehensive
gain
net
accumulated
deficit
total
stockholders
equity
total
liabilities
stockholders
equity
